Skip Navigation
Skip to contents

Endocrinol Metab : Endocrinology and Metabolism

clarivate
OPEN ACCESS
SEARCH
Search

Author index

Page Path
HOME > BROWSE ARTICLES > Author index
Search
Eun-Hee Cho  (Cho EH) 15 Articles
Diabetes, obesity and metabolism
Phloretin Ameliorates Succinate-Induced Liver Fibrosis by Regulating Hepatic Stellate Cells
Cong Thuc Le, Giang Nguyen, So Young Park, Hanh Nguyen Dong, Yun Kyung Cho, Jae-Ho Lee, Seung-Soon Im, Dae-Hee Choi, Eun-Hee Cho
Endocrinol Metab. 2023;38(4):395-405.   Published online August 3, 2023
DOI: https://doi.org/10.3803/EnM.2023.1661
  • 1,962 View
  • 117 Download
AbstractAbstract PDFPubReader   ePub   
Background
Hepatic stellate cells (HSCs) are the major cells which play a pivotal role in liver fibrosis. During injury, extracellular stimulators can induce HSCs transdifferentiated into active form. Phloretin showed its ability to protect the liver from injury, so in this research we would like to investigate the effect of phloretin on succinate-induced HSCs activation in vitro and liver fibrosis in vivo study.
Methods
In in vitro, succinate was used to induce HSCs activation, and then the effect of phloretin on activated HSCs was examined. In in vivo, succinate was used to generated liver fibrosis in mouse and phloretin co-treated to check its protection on the liver.
Results
Phloretin can reduce the increase of fibrogenic markers and inhibits the proliferation, migration, and contraction caused by succinate in in vitro experiments. Moreover, an upregulation of proteins associated with aerobic glycolysis occurred during the activation of HSCs, which was attenuated by phloretin treatment. In in vivo experiments, intraperitoneal injection of phloretin decreased expression of fibrotic and glycolytic markers in the livers of mice with sodium succinate diet-induced liver fibrosis. These results suggest that aerobic glycolysis plays critical role in activation of HSCs and succinate can induce liver fibrosis in mice, whereas phloretin has therapeutic potential for treating hepatic fibrosis.
Conclusion
Intraperitoneal injection of phloretin attenuated succinate-induced hepatic fibrosis and alleviates the succinate-induced HSCs activation.
Close layer
Adrenal gland
Glucocorticoids as a Double-Edged Sword in the Treatment of COVID-19: Mortality and Severity of COVID-19 in Patients Receiving Long-Term Glucocorticoid Therapy
Eun-Hee Cho
Endocrinol Metab. 2023;38(2):223-225.   Published online April 27, 2023
DOI: https://doi.org/10.3803/EnM.2023.201
  • 1,445 View
  • 75 Download
PDFPubReader   ePub   
Close layer
Diabetes, Obesity and Metabolism
Gemigliptin Alleviates Succinate-Induced Hepatic Stellate Cell Activation by Ameliorating Mitochondrial Dysfunction
Giang Nguyen, So Young Park, Dinh Vinh Do, Dae-Hee Choi, Eun-Hee Cho
Endocrinol Metab. 2022;37(6):918-928.   Published online November 15, 2022
DOI: https://doi.org/10.3803/EnM.2022.1530
  • 4,003 View
  • 235 Download
  • 3 Web of Science
  • 5 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Dipeptidyl peptidase-4 inhibitors (DPP-4Is) are used clinically as oral antidiabetic agents. Although DPP-4Is are known to ameliorate liver fibrosis, the protective mechanism of DPP-4Is in liver fibrosis remains obscure. In this study, gemigliptin was used to investigate the potential of DPP-4Is to alleviate the progression of liver fibrosis.
Methods
To clarify the effects and mechanisms of gemigliptin, we conducted various experiments in LX-2 cells (immortalized human hepatic stellate cells [HSCs], the principal effectors of hepatic fibrogenesis), which were activated by succinate and exhibited elevated expression of α-smooth muscle actin, collagen type 1, and pro-inflammatory cytokines and increased cell proliferation. In vivo, we examined the effects and mechanisms of gemigliptin on a high-fat, high-cholesterol–induced mouse model of nonalcoholic steatohepatitis (NASH).
Results
Gemigliptin decreased the expression of fibrogenesis markers and reduced the abnormal proliferation of HSCs. In addition, gemigliptin reduced the succinate-induced production of mitochondrial reactive oxygen species (ROS), intracellular ROS, and mitochondrial fission in HSCs. Furthermore, in the mouse model of NASH-induced liver fibrosis, gemigliptin alleviated both liver fibrosis and mitochondrial dysfunction.
Conclusion
Gemigliptin protected against HSC activation and liver fibrosis by alleviating mitochondrial dysfunction and ROS production, indicating its potential as a strategy for preventing the development of liver disease.

Citations

Citations to this article as recorded by  
  • Insulin Resistance, Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus: Clinical and Experimental Perspective
    Inha Jung, Dae-Jeong Koo, Won-Young Lee
    Diabetes & Metabolism Journal.2024; 48(3): 327.     CrossRef
  • Improvement effect of gemigliptin on salivary gland dysfunction in exogenous methylglyoxal-injected rats
    Woo Kwon Jung, Su-Bin Park, Hwa Young Yu, Junghyun Kim
    Heliyon.2024; 10(8): e29362.     CrossRef
  • Gemigliptin mitigates TGF-β-induced renal fibrosis through FGF21-mediated inhibition of the TGF-β/Smad3 signaling pathway
    Jun-Kyu Byun, Gwon-Soo Jung
    Biochemical and Biophysical Research Communications.2024; : 150425.     CrossRef
  • Gemigliptin, a DPP4 inhibitor, ameliorates nonalcoholic steatohepatitis through AMP-activated protein kinase-independent and ULK1-mediated autophagy
    Youngmi Song, Hyekyung Yang, Juhee Kim, Yoonjin Lee, Sung-Ho Kim, In-Gu Do, Cheol-Young Park
    Molecular Metabolism.2023; 78: 101806.     CrossRef
  • DPP-4 Inhibitor in Type 2 Diabetes Mellitus Patient with Non-Alcoholic Fatty Liver Disease: Achieving Two Goals at Once?
    Ji Cheol Bae
    Endocrinology and Metabolism.2022; 37(6): 858.     CrossRef
Close layer
Diabetes, Obesity and Metabolism
The Effects of Irisin on the Interaction between Hepatic Stellate Cell and Macrophage in Liver Fibrosis
Dinh Vinh Do, So Young Park, Giang Thi Nguyen, Dae Hee Choi, Eun-Hee Cho
Endocrinol Metab. 2022;37(4):620-629.   Published online July 22, 2022
DOI: https://doi.org/10.3803/EnM.2022.1412
  • 5,293 View
  • 205 Download
  • 4 Web of Science
  • 3 Crossref
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Hepatic stellate cells (HSCs) are the central players interacting with multiple cell types in liver fibrosis. The crosstalk between HSCs and macrophages has recently become clearer. Irisin, an exercise-responsive myokine, was known to have a potentially protective role in liver and renal fibrosis, especially in connection with stellate cells. This study investigated the effects of irisin on the interaction between HSCs and macrophages.
Methods
Tamm-Horsfall protein-1 (THP-1) human monocytes were differentiated into macrophages, polarized into the inflammatory M1 phenotype with lipopolysaccharide. Lieming Xu-2 (LX-2) cells, human HSCs, were treated with conditioned media (CM) from M1 macrophages, with or without recombinant irisin. HSCs responses to CM from M1 macrophages were evaluated regarding activation, proliferation, wound healing, trans-well migration, contractility, and related signaling pathway.
Results
CM from M1 macrophages significantly promoted HSC proliferation, wound healing, transwell migration, and contractility, but not activation of HSCs. Irisin co-treatment attenuated these responses of HSCs to CM. However, CM and irisin treatment did not induce any changes in HSC activation. Further, irisin co-treatment alleviated CM-induced increase of phopho-protein kinase B (pAKT), matrix metalloproteinase-9 (MMP-9), and tissue inhibitor of metalloproteinases-1 (TIMP-1).
Conclusion
These findings suggested that irisin may play a protective role in the pathogenesis of liver fibrosis, especially when working in the crosstalk between HSCs and macrophages.

Citations

Citations to this article as recorded by  
  • Matrix metalloproteinases induce extracellular matrix degradation through various pathways to alleviate hepatic fibrosis
    Liang Shan, Fengling Wang, Dandan Zhai, Xiangyun Meng, Jianjun Liu, Xiongwen Lv
    Biomedicine & Pharmacotherapy.2023; 161: 114472.     CrossRef
  • Potential role of irisin in digestive system diseases
    Yueming Zhang, Linxian Zhao, Huan Gao, Jinghui Zhai, Yanqing Song
    Biomedicine & Pharmacotherapy.2023; 166: 115347.     CrossRef
  • The effect of sarcopenia and serum myokines on prognosis and survival in cirrhotic patients: a multicenter cross-sectional study
    Salih Boga, Abdullah Emre Yildirim, Enver Ucbilek, Ali Riza Koksal, Sevil Tokdemir Sisman, Ibrahim Durak, Ilker Sen, Beril Dogu, Erdinc Serin, Ayse Bolat Ucbilek, Makbule Ozge Yildirim, Sukru Mehmet Erturk, Huseyin Alkim, Canan Alkim
    European Journal of Gastroenterology & Hepatology.2022; 34(12): 1261.     CrossRef
Close layer
Diabetes
Corrigendum: Correction of Table. Identification of Maturity-Onset Diabetes of the Young Caused by Glucokinase Mutations Detected Using Whole-Exome Sequencing
Eun-Hee Cho, Jae Woong Min, Sun Shim Choi, Hoon Sung Choi, Sang-Wook Kim
Endocrinol Metab. 2021;36(2):468.   Published online March 24, 2021
DOI: https://doi.org/10.3803/EnM.2021.202
Corrects: Endocrinol Metab 2017;32(2):296
  • 3,072 View
  • 82 Download
PDFPubReader   ePub   
Close layer
Endocrine Research
Irisin Regulates the Functions of Hepatic Stellate Cells
Hanh Nguyen Dong, So Young Park, Cong Thuc Le, Dae-Hee Choi, Eun-Hee Cho
Endocrinol Metab. 2020;35(3):647-655.   Published online September 22, 2020
DOI: https://doi.org/10.3803/EnM.2020.658
  • 6,836 View
  • 185 Download
  • 11 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   ePub   
Background
Hepatic stellate cells (HSCs) are known to play a fundamental role in the progression of liver fibrosis. Once HSCs are activated, they are involved in proliferation, migration, and contractility which are characteristics of liver fibrogenesis. Recent studies have shown that irisin, a myokine secreted during physical exercise, has a protective effect in various metabolic diseases, especially in renal fibrosis. However, whether irisin is involved in HSC activation and other processes associated with liver fibrosis has not yet been investigated. In this study, we reveal the role of irisin in HSC activation as well as in proliferation, migration, and contractile properties of HSCs in vitro.
Methods
LX-2 cells, immortalized human HSCs, were treated with transforming growth factor beta 1 (TGF-β1), a core regulator of HSC fibrosis, with or without irisin, and markers of the aforementioned processes were analyzed. Further, an inflammatory response was stimulated with TGF-β1 and lipopolysaccharide (LPS) in combination with irisin and the expression of cytokines was measured.
Results
Recombinant irisin significantly suppressed the expression of TGF-β1-stimulated fibrosis markers including alpha-smooth muscle actin and collagen type 1 alpha 1 and prevented the TGF-β1-induced proliferation, migration, and contractility of LX-2 cells. Additionally, irisin ameliorated the production of interleukin-6 (IL-6) and IL-1β induced by TGF-β1 and LPS treatments.
Conclusion
These findings suggested that irisin potently improved the progression of hepatic fibrosis by regulating HSC activation, proliferation, migration, contractility, and HSC-mediated production of inflammatory cytokine.

Citations

Citations to this article as recorded by  
  • Potential role of irisin in digestive system diseases
    Yueming Zhang, Linxian Zhao, Huan Gao, Jinghui Zhai, Yanqing Song
    Biomedicine & Pharmacotherapy.2023; 166: 115347.     CrossRef
  • Potential role of irisin in lung diseases and advances in research
    Hongna Dong, Xuejiao Lv, Peng Gao, Yuqiu Hao
    Frontiers in Pharmacology.2023;[Epub]     CrossRef
  • Stem bark of Fraxinus rhynchophylla ameliorates the severity of pancreatic fibrosis by regulating the TGF-β/Smad signaling pathway
    Ji-Won Choi, Joon Yeon Shin, Ziqi Zhou, Dong-Uk Kim, Bitna Kweon, Hyuncheol Oh, Youn-Chul Kim, Ho-Joon Song, Gi-Sang Bae, Sung-Joo Park
    Journal of Investigative Medicine.2022; 70(5): 1285.     CrossRef
  • Circadian rhythms and cancers: the intrinsic links and therapeutic potentials
    Li Zhou, Zhe Zhang, Edouard Nice, Canhua Huang, Wei Zhang, Yong Tang
    Journal of Hematology & Oncology.2022;[Epub]     CrossRef
  • Kinsenoside alleviates inflammation and fibrosis in experimental NASH mice by suppressing the NF-κB/NLRP3 signaling pathway
    Yan-fang Deng, Qian-qian Xu, Tian-qi Chen, Jia-xiong Ming, Ya-fen Wang, Li-na Mao, Jia-jun Zhou, Wei-guang Sun, Qun Zhou, Hong Ren, Yong-hui Zhang
    Phytomedicine.2022; 104: 154241.     CrossRef
  • The potential role of FNDC5/irisin in various liver diseases: awakening the sleeping beauties
    Xiaoyu Wang, Lihong Mao, Chaoqun Li, Yangyang Hui, Zihan Yu, Mingyu Sun, Yifan Li, Gaoyue Guo, Wanting Yang, Binxin Cui, Xiaofei Fan, Chao Sun
    Expert Reviews in Molecular Medicine.2022;[Epub]     CrossRef
  • The Effects of Irisin on the Interaction between Hepatic Stellate Cell and Macrophage in Liver Fibrosis
    Dinh Vinh Do, So Young Park, Giang Thi Nguyen, Dae Hee Choi, Eun-Hee Cho
    Endocrinology and Metabolism.2022; 37(4): 620.     CrossRef
  • Hepatic Steatosis Contributes to the Development of Muscle Atrophy via Inter-Organ Crosstalk
    Kenneth Pasmans, Michiel E. Adriaens, Peter Olinga, Ramon Langen, Sander S. Rensen, Frank G. Schaap, Steven W. M. Olde Damink, Florian Caiment, Luc J. C. van Loon, Ellen E. Blaak, Ruth C. R. Meex
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Physiopathology of Lifestyle Interventions in Non-Alcoholic Fatty Liver Disease (NAFLD)
    David Carneros, Guillermo López-Lluch, Matilde Bustos
    Nutrients.2020; 12(11): 3472.     CrossRef
Close layer
Adrenal gland
Update on the Aldosterone Resolution Score and Lateralization in Patients with Primary Aldosteronism
Eun-Hee Cho
Endocrinol Metab. 2018;33(3):352-354.   Published online September 18, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.352
  • 3,284 View
  • 33 Download
PDFPubReader   ePub   
Close layer
Miscellaneous
Corrigendum: Correction of Acknowledgments. Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women
Hoon Sung Choi, Hyang Ah Lee, Sang-Wook Kim, Eun-Hee Cho
Endocrinol Metab. 2018;33(3):428.   Published online August 14, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.3.428
  • 3,026 View
  • 40 Download
  • 1 Crossref
PDFPubReader   ePub   

Citations

Citations to this article as recorded by  
  • A novel residual graph convolution deep learning model for short-term network-based traffic forecasting
    Yang Zhang, Tao Cheng, Yibin Ren, Kun Xie
    International Journal of Geographical Information Science.2020; 34(5): 969.     CrossRef
Close layer
Bone Metabolism
Association between Serum Fibroblast Growth Factor 21 Levels and Bone Mineral Density in Postmenopausal Women
Hoon Sung Choi, Hyang Ah Lee, Sang-Wook Kim, Eun-Hee Cho
Endocrinol Metab. 2018;33(2):273-277.   Published online June 21, 2018
DOI: https://doi.org/10.3803/EnM.2018.33.2.273
  • 3,692 View
  • 53 Download
  • 8 Web of Science
  • 6 Crossref
AbstractAbstract PDFPubReader   ePub   
Background

Despite the beneficial effect of fibroblast growth factor 21 (FGF21) on metabolic disease, there are concerns about adverse effects on bone metabolism, supported by animal studies. However, a recent human study showed the positive association between serum FGF21 level and bone mineral density (BMD) in healthy premenopausal women. We undertook this study to examine the association between FGF21 level and BMD in healthy postmenopausal Korean women who are susceptible to osteoporosis.

Methods

We used data of 115 participants from a cohort of healthy postmenopausal women (>50 years old) to examine the association between serum FGF21 level and BMD. The clinical characteristics were obtained from the participants, and blood testing and serum FGF21 testing were undertaken. BMD of the lumbar spine, femoral neck and total hip area, and bone markers were used in the analyses.

Results

The mean age of the participants was 60.2±7.2 years. Serum FGF21 levels showed negative correlation with BMD and T-scores in all three areas, but there were no statistically significant differences. Multivariate analyses with adjustment for age and body mass index also did not show significant association between serum FGF21 level and BMD. In addition, serum FGF21 level also showed no correlation with osteocalcin and C-telopeptide levels.

Conclusion

In our study, serum FGF21 level showed no significant correlation with BMD and T-scores.

Citations

Citations to this article as recorded by  
  • Fibroblast growth factor 21 and bone homeostasis
    Yan Tang, Mei Zhang
    Biomedical Journal.2023; 46(4): 100548.     CrossRef
  • FGF21 negatively affects long-term female fertility in mice
    Beat Moeckli, Thuy-Vy Pham, Florence Slits, Samuel Latrille, Andrea Peloso, Vaihere Delaune, Graziano Oldani, Stéphanie Lacotte, Christian Toso
    Heliyon.2022; 8(11): e11490.     CrossRef
  • Potential role of fibroblast growth factor 21 in the deterioration of bone quality in impaired glucose tolerance
    D. T. W. Lui, C. H. Lee, V. W. K. Chau, C. H. Y. Fong, K. M. Y. Yeung, J. K. Y. Lam, A. C. H. Lee, W. S. Chow, K. C. B. Tan, Y. C. Woo, K. S. L. Lam
    Journal of Endocrinological Investigation.2021; 44(3): 523.     CrossRef
  • Skeletal Muscle and Bone – Emerging Targets of Fibroblast Growth Factor-21
    Hui Sun, Matthew Sherrier, Hongshuai Li
    Frontiers in Physiology.2021;[Epub]     CrossRef
  • Age‐related bone loss is associated with FGF21 but not IGFBP1 in healthy adults
    Shuen Yee Lee, Kai Deng Fam, Kar Ling Chia, Margaret M. C. Yap, Jorming Goh, Kwee Poo Yeo, Eric P. H. Yap, Sanjay H. Chotirmall, Chin Leong Lim
    Experimental Physiology.2020; 105(4): 622.     CrossRef
  • Chronic Kidney Disease Is Associated with Increased Plasma Levels of Fibroblast Growth Factors 19 and 21
    Małgorzata Marchelek-Myśliwiec, Violetta Dziedziejko, Monika Nowosiad-Magda, Katarzyna Dołęgowska, Barbara Dołęgowska, Andrzej Pawlik, Krzysztof Safranow, Magda Wiśniewska, Joanna Stępniewska, Maciej Domański, Kazimierz  Ciechanowski
    Kidney and Blood Pressure Research.2019; 44(5): 1207.     CrossRef
Close layer
Identification of Maturity-Onset Diabetes of the Young Caused by Glucokinase Mutations Detected Using Whole-Exome Sequencing
Eun-Hee Cho, Jae Woong Min, Sun Shim Choi, Hoon Sung Choi, Sang-Wook Kim
Endocrinol Metab. 2017;32(2):296-301.   Published online May 29, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.2.296
Correction in: Endocrinol Metab 2021;36(2):468
  • 4,964 View
  • 68 Download
  • 13 Web of Science
  • 11 Crossref
AbstractAbstract PDFPubReader   

Glucokinase maturity-onset diabetes of the young (GCK-MODY) represents a distinct subgroup of MODY that does not require hyperglycemia-lowering treatment and has very few diabetes-related complications. Three patients from two families who presented with clinical signs of GCK-MODY were evaluated. Whole-exome sequencing was performed and the effects of the identified mutations were assessed using bioinformatics tools, such as PolyPhen-2, SIFT, and in silico modeling. We identified two mutations: p.Leu30Pro and p.Ser383Leu. In silico analyses predicted that these mutations result in structural conformational changes, protein destabilization, and thermal instability. Our findings may inform future GCK-MODY diagnosis; furthermore, the two mutations detected in two Korean families with GCK-MODY improve our understanding of the genetic basis of the disease.

Citations

Citations to this article as recorded by  
  • Two novel GCK mutations in Chinese patients with maturity-onset diabetes of the young
    Tao Wang, Mengmeng Zhu, Yun Wang, Cheng Hu, Chen Fang, Ji Hu
    Endocrine.2023; 83(1): 92.     CrossRef
  • Maturity-onset diabetes of the young in a large Portuguese cohort
    Sílvia Santos Monteiro, Tiago da Silva Santos, Liliana Fonseca, Guilherme Assunção, Ana M. Lopes, Diana B. Duarte, Ana Rita Soares, Francisco Laranjeira, Isaura Ribeiro, Eugénia Pinto, Sónia Rocha, Sofia Barbosa Gouveia, María Eugenia Vazquez-Mosquera, Ma
    Acta Diabetologica.2022; 60(1): 83.     CrossRef
  • Maturity-Onset Diabetes of the Young: Mutations, Physiological Consequences, and Treatment Options
    Hazar Younis, Se Eun Ha, Brian G. Jorgensen, Arushi Verma, Seungil Ro
    Journal of Personalized Medicine.2022; 12(11): 1762.     CrossRef
  • Monogenic diabetes: recent updates on diagnosis and precision treatment: A narrative review
    Kyung Mi Jang
    Precision and Future Medicine.2022; 6(4): 209.     CrossRef
  • Monogenic diabetes characteristics in a transnational multicenter study from Mediterranean countries
    Martine Vaxillaire, Amélie Bonnefond, Stavros Liatis, Leila Ben Salem Hachmi, Aleksandra Jotic, Mathilde Boissel, Stefan Gaget, Emmanuelle Durand, Emmanuel Vaillant, Mehdi Derhourhi, Mickaël Canouil, Nicolas Larcher, Frédéric Allegaert, Rita Medlej, Asma
    Diabetes Research and Clinical Practice.2021; 171: 108553.     CrossRef
  • Etiologic distribution and clinical characteristics of pediatric diabetes in 276 children and adolescents with diabetes at a single academic center
    Ja Hye Kim, Yena Lee, Yunha Choi, Gu-Hwan Kim, Han-Wook Yoo, Jin-Ho Choi
    BMC Pediatrics.2021;[Epub]     CrossRef
  • Gençlerin Erişkin Başlangıçlı Diyabeti (MODY) Sorumlu HNF4A, GCK ve HNF1 Gen Varyasyonlarının Dünya Genelinde Coğrafik Dağılımı
    Deniz KANCA DEMİRCİ, Nurdan GÜL, İlhan SATMAN, Oguz OZTURK, Hülya YILMAZ AYDOĞAN
    Haliç Üniversitesi Fen Bilimleri Dergisi.2021; 4(1): 41.     CrossRef
  • Undernutrition and suboptimal growth during the first year are associated with glycemia but not with insulin resistance in adulthood
    Isabel Pereyra, Sandra López-Arana, Bernardo L. Horta
    Cadernos de Saúde Pública.2021;[Epub]     CrossRef
  • Update on Monogenic Diabetes in Korea
    Ye Seul Yang, Soo Heon Kwak, Kyong Soo Park
    Diabetes & Metabolism Journal.2020; 44(5): 627.     CrossRef
  • The epidemiology, molecular pathogenesis, diagnosis, and treatment of maturity-onset diabetes of the young (MODY)
    Ken Munene Nkonge, Dennis Karani Nkonge, Teresa Njeri Nkonge
    Clinical Diabetes and Endocrinology.2020;[Epub]     CrossRef
  • Novel deletion mutation in the glucokinase gene from a Korean man with GCK-MODY phenotype and situs inversus
    Yun Kyung Cho, Eun-Hee Cho, Hoon Sung Choi, Sang-Wook Kim
    Diabetes Research and Clinical Practice.2018; 143: 263.     CrossRef
Close layer
Serum Preadipocyte Factor 1 Levels Are Not Associated with Bone Mineral Density among Healthy Postmenopausal Korean Women
Hoon Sung Choi, Sang-Wook Kim, Eun-Hee Cho
Endocrinol Metab. 2017;32(1):124-128.   Published online February 28, 2017
DOI: https://doi.org/10.3803/EnM.2017.32.1.124
  • 3,492 View
  • 36 Download
  • 1 Web of Science
AbstractAbstract PDFSupplementary MaterialPubReader   
Background

Multipotent mesenchymal stem cells can differentiate into adipocytes or osteoblasts through closely regulated lineage-control processes. However, adipocyte precursor cells release preadipocyte factor 1 (Pref-1), which inhibits the differentiation of mesenchymal stem cells into mature adipocytes and osteoblasts. Previous studies have also reported an inverse association between Pref-1 levels and bone mineral density (BMD) among patients with anorexia nervosa.

Methods

In this retrospective study, we examined the correlations between Pref-1 levels and BMD among 124 healthy postmenopausal women (>50 years old). The patients had provided information regarding their clinical characteristics, and underwent blood testing and serum Pref-1 testing.

Results

The subjects' mean age was 59.9±7.1 years and the median time since menopause onset was 9.1 years. A history of osteoporotic fracture was identified in 23 subjects (19%). Serum Pref-1 levels were not significantly correlated with BMD values at the lumbar spine (R2=0.038, P=0.109), femur neck (R2=0.017, P=0.869), and total hip (R2=0.041, P=0.09), and multivariate analyses with adjustment for age and body mass index also did not detect any significant correlations. Subgroup analyses according to a history of fracture also did not detect significant associations between Pref-1 levels and BMD values.

Conclusion

In our study population, it does not appear that serum Pref-1 levels are significantly associated with BMD values and osteoporosis.

Close layer
Close layer
Clinical Study
Comparison of Age of Onset and Frequency of Diabetic Complications in the Very Elderly Patients with Type 2 Diabetes
Bong-Ki Lee, Sang-Wook Kim, Daehee Choi, Eun-Hee Cho
Endocrinol Metab. 2016;31(3):416-423.   Published online August 26, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.3.416
  • 3,491 View
  • 46 Download
  • 9 Web of Science
  • 9 Crossref
AbstractAbstract PDFPubReader   
Background

The prevalence of type 2 diabetes in elderly people has increased dramatically in the last few decades. This study was designed to clarify the clinical characteristics of type 2 diabetes in patients aged ≥80 years according to age of onset.

Methods

We reviewed the medical records of 289 patients aged ≥80 years with type 2 diabetes at the outpatient diabetes clinics of Kangwon National University Hospital from September 2010 to June 2014. We divided the patients into middle-age-onset diabetes (onset before 65 years of age) and elderly-onset diabetes (onset at 65+ years of age).

Results

There were 141 male and 148 female patients. The patients had a mean age of 83.2±2.9 years and the mean duration of diabetes was 14.3±10.4 years. One hundred and ninety-nine patients had elderly-onset diabetes. The patients with elderly-onset diabetes had a significantly lower frequency of diabetic retinopathy and nephropathy, lower serum creatinine levels, lower glycated hemoglobin (HbA1c) levels, and similar coronary revascularization and cerebral infarction rates compared to those with middle-age-onset diabetes. There was no frequency difference in coronary revascularization and cerebral infarction and HbA1c levels between three subgroups (<5, 5 to 15, and ≥15 years) of diabetes duration in elderly onset diabetes. However, both in the elderly onset diabetes and middle-age-onset diabetes, the cumulative incidence of retinopathy was increasing rapidly according to the duration of diabetes.

Conclusion

We report that individuals with elderly-onset diabetes have a lower frequency of diabetic retinopathy and nephropathy and similar cardiovascular complications compared to those with middle-age-onset diabetes.

Citations

Citations to this article as recorded by  
  • Rescue of High Glucose Impairment of Cultured Human Osteoblasts Using Cinacalcet and Parathyroid Hormone
    V. A. Shahen, A. Schindeler, M. S. Rybchyn, C. M. Girgis, B. Mulholland, R. S. Mason, I. Levinger, T. C. Brennan-Speranza
    Calcified Tissue International.2023; 112(4): 452.     CrossRef
  • Factors Related to the Occurrence and Number of Chronic Diabetic Complications in Patients with Type 2 Diabetes Mellitus: Utilizing The National Health Insurance Service-National Health Screening Cohort in Korea, 2002~2015
    Haejung Lee, Misoon Lee, Gaeun Park, Ah Reum Khang
    Journal of Korean Gerontological Nursing.2022; 24(1): 22.     CrossRef
  • Prevalence of and Risk Factors for Diabetic Retinopathy and Diabetic Macular Edema in Patients with Early- and Late-Onset Diabetes Mellitus
    Yu Wang, Zhong Lin, Gang Zhai, Xiao Xia Ding, Liang Wen, Dong Li, Bo Zou, Ke Mi Feng, Yuan Bo Liang, Cong Xie
    Ophthalmic Research.2022; 65(3): 293.     CrossRef
  • Associations of Age at Diagnosis and Duration of Diabetes With Morbidity and Mortality Among Older Adults
    Christine T. Cigolle, Caroline S. Blaum, Chen Lyu, Jinkyung Ha, Mohammed Kabeto, Judy Zhong
    JAMA Network Open.2022; 5(9): e2232766.     CrossRef
  • Chart Review of Diagnostic Methods, Baseline Characteristics and Symptoms for European Patients with Pancreatic Cancer
    Alfredo Carrato, Davide Melisi, Gerald Prager, Christoph B Westphalen, Anabel Ferreras, Nathalie D’Esquermes, Julien Taieb, Teresa M Mercadé
    Future Oncology.2021; 17(15): 1843.     CrossRef
  • Distinction of cardiometabolic profiles among people ≥75 years with type 2 diabetes: a latent profile analysis
    Antoine CHRISTIAENS, Michel P. HERMANS, Benoit BOLAND, Séverine HENRARD
    BMC Endocrine Disorders.2019;[Epub]     CrossRef
  • Validity of diagnostic codes and estimation of prevalence of diabetic foot ulcers using a large electronic medical record database
    Avivit Cahn, Talya Altaras, Tal Agami, Ori Liran, Colette E. Touaty, Michel Drahy, Rena Pollack, Itamar Raz, Gabriel Chodick, Inbar Zucker
    Diabetes/Metabolism Research and Reviews.2019;[Epub]     CrossRef
  • Response: Comparison of Age of Onset and Frequency of Diabetic Complications in the Very Elderly Patients with Type 2 Diabetes (Endocrinol Metab2016;31:416-23, Bong-Ki Lee et al.)
    Eun-Hee Cho
    Endocrinology and Metabolism.2017; 32(1): 142.     CrossRef
  • Letter: Comparison of Age of Onset and Frequency of Diabetic Complications in the Very Elderly Patients with Type 2 Diabetes (Endocrinol Metab2016;31:416-23, Bong-Ki Lee et al.)
    Mee Kyoung Kim
    Endocrinology and Metabolism.2017; 32(1): 140.     CrossRef
Close layer
Close layer
Clinical Study
High Levels of Serum DPP-4 Activity Are Associated with Low Bone Mineral Density in Obese Postmenopausal Women
Sang-Wook Kim, Eun-Hee Cho
Endocrinol Metab. 2016;31(1):93-99.   Published online March 16, 2016
DOI: https://doi.org/10.3803/EnM.2016.31.1.93
  • 3,740 View
  • 39 Download
  • 11 Web of Science
  • 13 Crossref
AbstractAbstract PDFPubReader   
Background

Dipeptidyl peptidase 4/CD26 (DPP-4) is a widely expressed cell surface serine protease. DPP-4 inhibitors, one of common anti-diabetic agents play a protective role in bone metabolism in recent studies. A soluble form of DPP-4 is found in serum, and exhibits DPP-4 enzymatic activity. However, the physiological role of serum or soluble DPP-4 and its relationship with DPP-4 enzymatic function remain poorly understood. The aims of current study were to determine the association between serum DPP-4 activity and bone mineral density (BMD) in postmenopausal women.

Methods

We recruited data and serum samples from 124 consecutive healthy postmenopausal women aged >50 years. We divided study subjects into obese (body mass index [BMI] ≥25 kg/m2) and non-obese (BMI <25 kg/m2) postmenopausal women and examined the correlation between serum DPP-4 activity and clinical variables in each groups.

Results

A total of 124 postmenopausal women was enrolled, with a mean age of 59.9±7.1 years. The mean BMI of the study patients was 24.4±2.8 kg/m2. Regarding bone turnover markers, serum DPP-4 activity was positively correlated with serum calcium concentrations, intact parathyroid hormone, and serum C-telopeptide levels in all of the study subjects. However, there was no association between serum DPP-4 activity and BMD in the spine or femoral neck in all of the study subjects. Serum DPP-4 activity was negatively correlated (R=−0.288, P=0.038) with BMD of the spine in obese postmenopausal women.

Conclusion

This study demonstrated for the first time that serum soluble DPP-4 activity was negatively correlated with BMD in obese postmenopausal women.

Citations

Citations to this article as recorded by  
  • A novel mechanism of Vildagliptin in regulating bone metabolism and mitigating osteoporosis
    Jinwen He, Dacheng Zhao, Bo Peng, Xingwen Wang, Shenghong Wang, Xiaobing Zhao, Peng Xu, Bin Geng, Yayi Xia
    International Immunopharmacology.2024; 130: 111671.     CrossRef
  • Comparative evaluation of Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors influence on bone turnover markers in rats with experimental type 2 diabetes mellitus
    N. V. Timkina, A. V. Simanenkova, T. L. Karonova, T. D. Vlasov, N. Yu. Semenova, А. A. Bairamov, V. A. Timofeeva, A. A. Shimshilashvili, E. V. Shlyakhto
    Osteoporosis and Bone Diseases.2022; 24(4): 27.     CrossRef
  • The relationship between bone marrow adipose tissue and bone metabolism in postmenopausal osteoporosis
    Jiao Li, Xiang Chen, Lingyun Lu, Xijie Yu
    Cytokine & Growth Factor Reviews.2020; 52: 88.     CrossRef
  • Update on: effects of anti-diabetic drugs on bone metabolism
    Guillaume Mabilleau, Béatrice Bouvard
    Expert Review of Endocrinology & Metabolism.2020; 15(6): 415.     CrossRef
  • Soluble Dipeptidyl Peptidase-4 Levels Are Associated with Decreased Renal Function in Patients with Type 2 Diabetes Mellitus
    Eun-Hee Cho, Sang-Wook Kim
    Diabetes & Metabolism Journal.2019; 43(1): 97.     CrossRef
  • Marrow Adipose Tissue: Its Origin, Function, and Regulation in Bone Remodeling and Regeneration
    Qiwen Li, Yunshu Wu, Ning Kang
    Stem Cells International.2018; 2018: 1.     CrossRef
  • Association between Serum Dipeptidyl Peptidase-4 Concentration and Obesity-related Factors in Health Screen Examinees
    Ji Yeon Lee, Byoung Kuk Jang, Min Kyung Song, Hye Soon Kim, Mi-Kyung Kim
    Journal of Obesity & Metabolic Syndrome.2017; 26(3): 188.     CrossRef
  • Association of DPP-4 activity with BMD, body composition, and incident hip fracture: the Cardiovascular Health Study
    L. D. Carbone, P. Bůžková, H. A. Fink, J. A. Robbins, M. Bethel, C. M. Isales, W. D. Hill
    Osteoporosis International.2017; 28(5): 1631.     CrossRef
  • Adipocyte Accumulation in the Bone Marrow during Obesity and Aging Impairs Stem Cell-Based Hematopoietic and Bone Regeneration
    Thomas H. Ambrosi, Antonio Scialdone, Antonia Graja, Sabrina Gohlke, Anne-Marie Jank, Carla Bocian, Lena Woelk, Hua Fan, Darren W. Logan, Annette Schürmann, Luis R. Saraiva, Tim J. Schulz
    Cell Stem Cell.2017; 20(6): 771.     CrossRef
  • The emerging role of bone marrow adipose tissue in bone health and dysfunction
    Thomas H. Ambrosi, Tim J. Schulz
    Journal of Molecular Medicine.2017; 95(12): 1291.     CrossRef
  • Articles inEndocrinology and Metabolismin 2016
    Won-Young Lee
    Endocrinology and Metabolism.2017; 32(1): 62.     CrossRef
  • Dipeptidyl Peptidase-4 and Adolescent Idiopathic Scoliosis: Expression in Osteoblasts
    Emilie Normand, Anita Franco, Alain Moreau, Valérie Marcil
    Scientific Reports.2017;[Epub]     CrossRef
  • Effect of Dipeptidyl Peptidase-4 Inhibitors on Bone Metabolism and the Possible Underlying Mechanisms
    Yinqiu Yang, Chenhe Zhao, Jing Liang, Mingxiang Yu, Xinhua Qu
    Frontiers in Pharmacology.2017;[Epub]     CrossRef
Close layer

Endocrinol Metab : Endocrinology and Metabolism